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However, component-resolved diagnosis using puriﬁed and
recombinant allergens can improve the accuracy of speciﬁc IgE
testing, but availability is limited. Treatment options for HDM
allergy are limited and include HDM avoidance, which is widely
recommended as a strategy, although evidence for its efﬁcacy
is variable. Clinical efﬁcacy of pharmacotherapy is well
documented; however, symptom relief does not extend beyond
the end of treatment. Finally, allergen immunotherapy has a poor
but improving evidence base (notably on sublingual tablets) and
its beneﬁts last after treatment ends. This review identiﬁes needs
for deeper physician knowledge on the extent and impact of
HDM allergy in respiratory disease, as well as further
development and improved access to molecular allergy diagnosis.
Furthermore, there is a need for the development of better-
designed clinical trials to explore the utility of allergen-speciﬁc
approaches, and uptake of data into guidance for physicians on
more effective diagnosis and therapy of HDM respiratory allergy
in practice.  2015 The Authors. Published by Elsevier Inc. on
behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(J Allergy Clin Immunol Pract 2015;3:843-55)
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House dust mite (HDM) allergy is strongly implicated in the
pathogenesis of respiratory allergic disease,1,2 and a large pro-
portion of patients with allergic rhinitis (AR), allergic asthma
(AA), or both are sensitized to HDM, predominantly Dermato-
phagoides pteronyssinus and Dermatophagoides farinae.3-6
Disease management according to guidelines has traditionally
focused on allergen avoidance and alleviation of symptoms by
pharmacotherapy. However, accurate diagnosis of HDM sensi-
tization is not easy in primary care, and symptomatic relief from
pharmacotherapy ceases as soon as treatment ends. Allergen
immunotherapy (AIT) has been shown to address the underlying
allergic cause safely and effectively, with lasting effect after the
end of treatment.7 However, relevant guidelines are cautious in
their recommendations to physicians owing to gaps in the evi-
dence base, particularly heterogeneity of trial design, especially
end points,8 dosing, and duration of treatment.9-16 Conse-
quently, patients sensitized to HDM can experience delay in
obtaining accurate diagnosis and effective, lasting treatment.
These delays can be exacerbated by the low priority ascribed by843
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SPT- Skin prick testpatients and doctors and by the low number of allergy specialists
in many countries.17
Until now, HDM allergy has been diagnosed by a clinical
history of HDM exposure in combination with HDM sensiti-
zation18 demonstrated by a combination of skin prick tests
(SPTs) and speciﬁc IgE testing, with or without nasal challenge
tests. Mite allergens (characterized in 24 groups according to
their molecular proﬁle and likely activity3) consist of body
proteins and digestive enzymes within cells that have become
detached from the gut wall and discharged within fecal pellets.3
The recent availability of DNA sequences of allergens has
enabled the preparation of puriﬁed, recombinant allergens and
hypoallergenic allergen derivatives, which can be used for
component-resolved diagnosis (CRD) to identify the individual
molecules to which a patient is sensitized19-21 and also for
monitoring the progress of AIT.22,23 This approach comple-
ments the information gained from SPT and IgE testing with
nonpuriﬁed allergen extracts, and can distinguish between true
polysensitization to multiple allergens and false-positive results
resulting from cross-reactivity.24,25
The efﬁcacy of HDM avoidance has been widely ques-
tioned.26,27 Although an intuitive strategy, avoidance is not
supported by robust evidence of efﬁcacy, and some controversy
has arisen over the impartiality of inclusion criteria in reviews.
Despite this, avoidance is still widely recommended to reduce the
severity of AR or AA symptoms in sensitized individuals, and
may be effective as part of a holistic approach combining
avoidance of tobacco smoke, improved education, and regular
assessment.29,30 The main impact of avoidance may be in babies
with a familial genetic predisposition to asthma because inter-
vention in childhood is effective in controlling asthma in atopic
children.31 In any case, the effectiveness of avoidance depends on
speciﬁc allergen diagnosis.
Treatment of AR and AA by pharmacological agents has a
solid evidence base of effective and safe treatment. However,
many of the standard drugs have not been tested speciﬁcally in
the context of HDM allergy and many HDM-allergic patients
achieve only poor to moderate symptom control.32 This evidence
gap may be relevant in relation to less-than-adequate control or
frequent recurrence of symptoms, given the potential for varying
responses to different medications.12
Developments in immunotherapy are continuing to build on the
successful demonstration of the safety and efﬁcacy of both subcu-
taneous immunotherapy (SCIT) and sublingual immunotherapy
(SLIT) in both reducing symptom burden and use of pharmaco-
therapeutic medication. Both SCIT and SLIT require treatment
over several years, and SCIT must be given under medical super-
vision. Therefore, both SCIT and SLIT can suffer from low patientadherence, especially toward the end of treatment, and efforts to
improve adherence would improve outcomes until such time as
shorter treatment regimens may become available.33
SLIT has a superior safety proﬁle to SCIT because it has a
lesser risk of anaphylaxis, plus the advantage to patients of home
administration and less commitment of time33; it also may
prevent new sensitizations.34 Evidence is now appearing on the
efﬁcacy, safety, and optimal dosing of SLIT tablets.35,36 In
addition to alleviating AR, the beneﬁts extend to patients with
mild to moderate HDM-induced AA37 and enable reduced use
of inhaled corticosteroids.38
Both speciﬁc diagnosis and effective, lasting treatment of
HDM-induced respiratory disease present challenges. The greatest
need in promoting more effective diagnosis is to increase aware-
ness among primary care physicians of current techniques that can
complement the information provided by SPT and IgE testing
and increase referrals to allergists who have access to them. The
most compelling need to improve treatment is generation of more
robust clinical data on the effectiveness of avoidance and immu-
notherapy. Such data, which can contribute the most reliable
foundation for more speciﬁc guidelines, depend on the conduct of
randomized, double-blind, placebo-controlled trials.
METHODS
A series of pilot PubMed searches were used to identify the most
appropriate key words, which were cross-referenced with MeSH
terms. Search terms were then amalgamated into 2 groups speciﬁc to
HDM allergy: disease or immunotherapy (Figure 1). The individual
search terms used were asthma; allergic asthma; allergic rhinitis;
respiratory allergic disease; allergic march; dust mite; pulmonol*,
allerg*. The composite search terms used for disease were asthma þ
dust mite, allergic rhinitis þ dust mite, respiratory allergic disease þ
dust mite, allergic march þ dust mite, house dust mite allergy, and
dust mite allergy. The composite search terms for immunotherapy
were sublingual immunotherapy OR subcutaneous immunotherapy
OR aller* immunotherapy tablet þ asthma OR allergic rhinitis OR
dust mite; immunotherapy þ dust mite. A separate search was
carried out for references to pharmacotherapy speciﬁc to HDM,
using the term dust mite þ relevant pharmacotherapy categories,
and also dust mite þ individual pharmacotherapies.
Information on the level of evidence relating to currently used
pharmacological interventions for AR, AA, and HDM allergy with
AR or AA was compiled from the Allergic Rhinitis and its Impact on
Asthma (ARIA) and the Global Initiative for Asthma (GINA)
guidelines and literature searches (Table I). A PubMed search was
conducted for treatment of asthma/allergic rhinitis/dust mite, and
ﬁlters applied for publication type (meta-analysis, clinical trial).
PubMed and the Cochrane Library were searched for dust mite þ
pharmacotherapy interventions (categories and individual drugs).
Clinical aspects of the HDM allergy patient
Asthma and rhinitis have long been recognized as heterogenic
diseases. In asthma particularly, a growing interest in symptomatic
phenotypes may also extend to endotypes that reﬂect etiology.39,40
Cluster analysis has helped reﬁne such categories, paving the way
for personalized medicine.16,41 The clinical phenotypes of asthma
and rhinitis relevant to allergy are encompassed in the term “respi-
ratory allergic disease” and the concept of a united allergic airway
reﬂects a shared underlying mechanism of pathogenesis.42 HDM
sensitization is a major cause of perennial AR and AA symptoms,
and hence a major causative factor in respiratory allergic disease.
FIGURE 1. Search methodology. Methodology of individual and composite literature searches to identify literature relevant to AR and/or
AA related to HDMs, and their treatment. Additional specific searches were conducted using asthma, allergic rhinitis, and dust mite, with
interventions as associated keywords, and filters applied for publication type (meta-analysis, clinical trial) and age of publication up to
2013. Categories of evidence are based on Shekelle et al,43 adapted by Cox et al.44
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patients who have already developed asthma. For example, the Eu-
ropean Community Respiratory Health Survey (n ¼ 12,687, 20.2%
of whom had allergy to HDM) found an association between HDM
allergy and lung function in HDM-sensitized patients with asthma.
Speciﬁcally, FEV1 was reduced by 119 mL in women and 112 mL in
men when compared with patients with asthma who were not
HDM-sensitized, and a lower FEV1/forced vital capacity ratio was
also observed (1.95% and 2.48%, respectively).45
Exposure to HDM allergens in adults with asthma not previously
sensitized to HDM increases asthma morbidity,46,47 and those
already sensitized have an increased severity of asthma.48,49 A study
conducted in 30 centers across 13 countries from Europe, Australia/
New Zealand, and the United States found a strong association be-
tween sensitization toD pteronyssinus (adjusting for age, sex, smoking,
passive smoking, parental history of asthma, and region) and asthma
severity (1.61 [1.14-2.26]; P < .002).50 Speciﬁcally, sensitization to
HDM is a risk factor for recurrent asthma exacerbations.51 Over time,
patients with HDM sensitization are likely to experience concomitant
rhinitis and asthma. In a general population study of 734 Danish
adults without asthma symptoms who were examined on 2 occasions,
8 years apart, the risk of new asthma symptoms was many times
higher in persons with AR at the beginning of the study than in those
without (7.8 times for AR to pollens, 17.8 times for AR to animals,
and 37.6 times for AR to mites) (Figure 2).52 The highest risk was
found for those with HDM-related AR.52
The comorbidity of AA and AR is likely to worsen each condi-
tion,53 increasing the likelihood of patients reaching a “moderate-
severe” state. This is consistent with the concept of “one airway,”
and it is also noteworthy that the severity of rhinitis parallels the
severity of asthma, and vice versa.54
However, identifying a speciﬁc set of symptoms particular to
HDM allergy is difﬁcult because patients often have concomitant
allergies. One possible avenue for future research is the degree towhich allergies, and particularly HDM allergy, contribute to wors-
ening the symptoms of asthma. For instance, a subgroup of 5% to
10% of the patients with mild to moderate asthma does not respond
to mainstream controller medications, and AR is indicated as one of
the major factors that can inﬂuence the effectiveness of asthma
treatments in everyday clinical practice.55 In this respect, sensitiza-
tion to HDM may be a contributory factor to symptom severity.
In summary, HDM sensitization is a major causative factor in
respiratory allergic disease that is implicated in both AR and AA.
Comorbidity of HDM-related rhinitis and asthma can reduce lung
function and increase the severity of asthma.
Issues affecting the patient pathway
Extent and impact of delayed diagnosis. Accurate
diagnosis and appropriate treatment planning may be considerably
delayed in HDM allergy,32,56 and reﬁning the initial diagnosis of
rhinitis or asthma with the identiﬁcation of relevant allergic sensi-
tizations may help physicians to implement individualized strategies
for treatment. Surprisingly, a survey of patients with respiratory
disease from 10 European countries (n ¼ 7004) found that an
average of 33% (between 15% in Germany and 68% in the United
Kingdom) had never received a diagnostic test for allergy, even
though almost half of these (48%) had been seen by their family
doctor.57 Only 16% of the study population was treated with AIT;
thus, treatment was limited to symptomatic medication for patients
who had not undergone diagnostic testing for allergy.57 A separate
study of 411 adult patients from 6 European countries with clinically
conﬁrmed AR (from any cause) drawn from a random sample of
9646 (1600-1625 per country) found that 45% did not have a
previous physician’s diagnosis.56
A contributing factor may be low public awareness of HDM
allergy as a treatable condition. For example, a quantitative study of
patients’ perceptions of HDM allergy in 4016 people from France,
Italy, Germany, and Spain showed a signiﬁcant gap between the
TABLE I. Levels of evidence for currently used pharmacological interventions for AR, AA, and HDM allergy with AR or AA
Pharmacotherapy
Level of evidence
AR/rhinoconjunctivitis Asthma HDM respiratory allergy (AR or AA)
Anticholinergics 1b 1a NR
Antihistamines (second- generation H1)




Oral 1a 1a 1b58-60
Anti-IgE (omalizumab and others) 1b 1a/1b 1b61-63
b2-agonists
Rapid-acting inhaled NR 1b 1b64
Short-acting oral NR 1b NR
Long-acting inhaled 1b 1a 2b65
LB66,67
Long-acting oral 1b 1a NR
Decongestants
Intranasal 1b NR 1b68,69
Oral 1b NR NR
Corticosteroids
Inhaled 1b 1a 1a70
Intranasal 1a 1a 2b71
Ocular 1a NR NR
Systemic 1b 1a LB72
Leukotriene modiﬁers 1a 1a 1b73
Nedocromil sodium NR NR 2b74
Sodium cromoglycate 1b 1b NR
Theophylline NR 1a LB75
Categories of evidence
1a Evidence from meta-analysis of randomized controlled trials
1b Evidence from at least 1 randomized controlled trial
2a Evidence from at least 1 controlled study without randomization
2b Evidence from at least 1 other type of quasi-experimental study
3 Evidence from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies
4 Evidence from expert committee reports or opinions, clinical experience of respected authorities, or both
LB Evidence from laboratory-based studies
NR Not rated
Categories of evidence are based on Shekelle et al,43 adapted by Cox et al.44
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proportion of participants with potential symptoms of HDM allergy
(57%), and the actual proportion of participants diagnosed with
HDM allergy (15%).76 Many patients in this study felt that HDM
allergy was “something you must accept and live with”.76 Similarly,
an earlier study of 726 Danish patients with asthma and/or rhinitis
found that 75% were allergic, and asthma was undiagnosed and
untreated in 50% of all those with asthma and undertreated ac-
cording to GINA guidelines in 76%. Rhinitis was undiagnosed in
32% of the patients, and 83% with moderate to severe rhinitis were
undertreated.77
Delays in effective diagnosis and treatment for AR can affect the
changing pathophysiology of the disease. Given the progressive
nature of allergy, AR should be considered both a predictor of
asthma78,79 and a risk factor for asthma.54,80 The presence of AR in
55.2% of the patients with asthma (95% CI, 54.4%-56.0%) in-
dicates the level of comorbidity, and in addition, AR is associated
with more severe asthma, more difﬁcult to control asthma, andreduced quality of life.54,80 However, the ARIA guidelines are not
focused on investigating etiological factors. More acute clinician
awareness of and adherence to ARIA guidelines, along with an
evaluation of “disease control” parallel to that used in GINA,81
might encourage physicians to respond with better management of
symptom deterioration.82
A lack of resources often contributes to delayed diagnosis of al-
lergy. A survey of 33 countries conducted by the World Allergy
Organization Specialty and Training Council concluded that
insufﬁcient allergists were available. Patients with AA were more
likely to see relatively poorly trained or allergy-naive system spe-
cialists, generalists, or primary care physicians.17 Moreover, a survey
of allergy management in primary care across European countries
found that nonallergist pneumology or pulmonology specialists were
more likely than allergists to receive referrals and that 20.6% of the
practitioners in primary care had no access to allergy tests at all.83
Also, in some countries, allergy is a specialist discipline, whereas in
others it is considered a subspecialty or not a specialty at all.84
FIGURE 2. The risk of development of new asthma symptoms is
high in AR. The highest risk of novel asthma symptoms in a
general population of Danish adults was found for those with
HDM-related AR.52 The y-axis refers to the percentage of patients
with AR related to sensitization to pollens, animals, or HDMs who
developed asthma symptoms, grouped by the presence or
absence of AR at the start of the study. 95% CIs are indicated.
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do not use any medication, often because of concerns over cost,32
whereas others self-treat using over-the-counter remedies.85 A
questionnaire-based patient survey found that up to two-thirds of
people with respiratory, skin, or food allergies did not seek help until
symptoms became intolerable,32 but without medical help patients
suffer sleep disturbance and cognitive impairment and are at risk of
developing further sensitizations.86 Notably, undertreatment is
equally related to physicians: a direct comparison of the perception
of AR symptoms in diagnostically conﬁrmed patients by both pa-
tients and physicians found that physicians were likely to underrate
the prevalence and severity of ocular symptoms and headache,
cough, wheezing, and nocturnal waking and to underdiagnose
asthma among patients with AR.87 This underdiagnosis is surprising,
considering the negative impact of AR on sleep,88 concentration and
productivity at work89,90 or school,91,92 fatigue and mood changes,93
anxiety94 and depression,95 and overall quality of life.89
Accurate diagnosis of HDM allergy can be challenging, and large-
scale patient surveys suggest that as many as 45% of the patients
with conﬁrmed HDM allergy had no previous diagnosis. More acute
clinician awareness of, and adherence to, rhinitis guidelines, as well
as an evaluation of “disease control” parallel to that used in GINA,
might encourage physicians to respond with closer management of
symptom deterioration.
Impact of nonadherence. The efﬁcacy of conventional
pharmacological interventions in rhinitis is currently undermined
by poor adherence96; typically only 48.7% of the patients follow
physicians’ directions, with 34.3% adapting the prescription.97
Adherence to prescribed treatment depends on complex relation-
ships between efﬁcacy, safety, onset of action, cost of medication,
conﬁdence in physician, and patient characteristics (psychosocialproﬁle, socioeconomic status).98 For example, a study of primary
practice in Spain found that of the patients referred to allergy
specialists, 86.2% had moderate to severe HDM-related disease
(n ¼ 519); however, good treatment control had previously been
achieved by pharmacotherapy in only 43% of the cases.99 Thus,
support of the patients’ education and subsequent improved
adherence to the prescribed regimen may improve outcomes.98
Adherence to medication also plays a strong role in asthma
management because patients may react to deterioration in symptom
control by adjusting medication inappropriately.100 Patient adher-
ence is therefore an important factor in successful treatment of
HDM-related respiratory disease because it can be almost half of the
cases for both AR and AA.
Improving diagnostic procedures. Mite allergens, classi-
ﬁed within allergen groups 1 to 24 according to their molecular
structure and likely mode of action,3 consist of body proteins and
digestive enzymes contained within dissociated cells from the mite
gut wall and retained within fecal pellets.3 The 2 most dominant are
cysteine protease (group 1) and lipid-binding protein capable of
mimicking the Toll-like receptor 4 coreceptor MD-2 (group 2).3
Another potent allergen group is the chitin-binding proteins group
(group 23), typiﬁed by Der p 23. This group of proteins has been
shown to elicit speciﬁc IgE reactivity in more than 70% of HDM-
sensitive patients, and basophil activation even at less than one-
tenth of the concentration of the major allergen, Der p 1.101
Group 1 cysteine proteases are variable in form and induce both
species-speciﬁc and cross-reactive IgE antibodies, whereas group 2
allergens Der p 2, Der f 2, and Eur m 2 are highly cross-reactive
between species.102 Because of this, it is not possible to prove the
sensitization of a patient to only 1 speciﬁc mite species. This presents
diagnostic issues for the small percentage of sensitized individuals
who are reactive to allergens from other groups but not to allergens
from groups 1 or 2.103
To improve identiﬁcation of HDM allergy, greater awareness of
immunodiagnostic procedures is needed at the point of care. Two
key diagnostic tools indicate HDM sensitization: either by direct
in vitro measurement of HDM-speciﬁc IgE in serum or by indirect
in vivo demonstration of HDM-speciﬁc IgE on cutaneous mast cells
via an SPT. These 2 standard methods are now complemented to a
limited extent by the development of CRD, which can identify
critical allergens and enhance treatment.
Survey data report a wide variance in SPT although it is a core
diagnostic tool.104 Therefore, widespread acceptance of a standard-
ized protocol with standardized allergen extracts is needed to
improve accuracy.23,105 However, multiallergenic screening of spe-
ciﬁc IgE is helpful in the case of multiple sensitizations to establish
the relative impact of individual allergens, and may have a particular
utility in general practice.7 Variations between locations and meth-
odology of allergen testing, concentration of solutions, and cross-
reactivity may have an impact on the accuracy of either test results.
Both SPT and speciﬁc IgE testing show satisfactory qualitative,
but not necessarily quantitative, agreement owing to a number of
biological variables in SPT besides simple speciﬁc IgE concentra-
tions. Standardization of the protocol for either test is clearly
important, considering that batch-to-batch variations in the allergen
content of extracts, lack or poor representation of allergens, poor
immunogenicity of certain allergens, varying allergenic activities,
presence of nonallergenic materials, and contamination may all affect
test results.106,107 Approaches used over the last 100 years to
improve the quality of natural allergen extracts for immunotherapy
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logical activity, and antibody-based measurement of allergen
content.23
Because of extensive interspecies cross-reactivity, testing for
sensitivity to 1 HDM species (ie, Der p or Der f) is sufﬁcient in most
cases. Current commercially available HDM extracts contain vari-
able amounts of major allergens Der p 1 (group 1) and Der p 2
(group 2), whereas other important allergens (eg, Der p 23) may be
underrepresented or absent.101 Consequently, some HDM-allergic
individuals, particularly those without sensitization to group 1 and
2 HDM allergens, might remain undetected with the use of available
HDM extracts.101 Thus, molecular allergy diagnosis including all
major HDM allergens, and/or improved HDM extracts, would be
needed to close this diagnostic gap.
IgE for speciﬁc HDM allergens can also be detected by using an
alternative molecular allergy diagnostic protocol from ImmunoCAP
(Thermo Fisher Scientiﬁc, Uppsala, Sweden). So far, this approach
does not carry any advantages compared with the use of HDM
extracts because up to 97% of Der pesensitized individuals can be
diagnosed by a combination of Der p 1 and Der p 2.103 However,
proof of sensitization to group 1 and group 2 HDM allergens could
be useful because most available HDM extracts are standardized on
the basis of these major allergens. A microarray screening platform
with 112 allergenic molecules from 51 allergen sources enables semi-
quantitative detection of speciﬁc IgE to nDer p 1, rDer p 2, and
rDer p 10. This test includes additional major and minor HDM
allergens, allowing the investigation of “molecular spreading” in
HDM-allergic individuals. This observation, driving IgE-mediated
sensitizations from a limited number of single allergens to a more
complex IgE repertoire covering many major and minor HDM al-
lergens, might be associated with more severe and/or lower airway
disease. In the situation of a no clear-cut case history, conjunctival or
nasal challenge tests with appropriate HDM extracts (Der p or Der f)
may support the diagnosis of HDM sensitization and conﬁrm its
mucosal effect.
The use of CRD to measure the amount of speciﬁc IgE that binds
to puriﬁed natural allergen components or recombinant cross-reactive
allergen components can enable identiﬁcation of the individual
molecules to which a patient is sensitized.19-21 This approach can add
useful information to what is already known from SPT and speciﬁc
IgE tests, considering that the critical allergen for treatment can be
identiﬁed and the most appropriate treatment chosen. The avail-
ability of DNA sequences of allergens since 1988 has enabled
preparation of puriﬁed, deﬁned recombinant allergens and hypoal-
lergenic allergen derivatives that can be used for CRD.23 The
technique can distinguish true polysensitization from the positive
results from cross-reactive components, whereas SPT cannot.24,25
This could have signiﬁcant implications for therapy options
because the multiallergen immunotherapy indicated by poly-
sensitization could offer exposure to irrelevant allergens in the case of
cross-reactivity. Treating the monosensitized patient with only the
clinically relevant puriﬁed allergens has been suggested to offer a way
to avoid new sensitizations.21
CRD can also be useful in monitoring the progress of AIT
because IgE-mediated reactions decrease in line with a rise in the
level of speciﬁc IgG4 antibodies, in response to effective immuno-
therapy.22 The immune response can be monitored and therapy
adjusted, if necessary, which may improve compliance.19
In summary, extensive interspecies cross-reactivity makes it
impossible to prove sensitization to a HDM species using SPT and
IgE testing with unpuriﬁed extracts. Accuracy can be improved byCRD, which can identify the individual molecules to which a patient
is sensitized and distinguish between true polysensitization and
cross-reactivity. A further advantage is that CRD can also be used to
monitor the course of AIT and to assess compliance. In addition, use
of recombinant allergens in diagnostic tests can compensate for the
variability of natural allergen extracts.
Treatment options. Following diagnosis, 3 therapeutic options
are currently available for respiratory allergic disease caused by HDM
allergy: (1) allergen avoidance, (2) pharmacological intervention, and
(3) AIT. Allergen avoidance and AIT can be implemented only after
the identiﬁcation of the speciﬁc underlying allergy.
Effectiveness of avoidance measures
Avoidance strategies in HDM allergy are primarily based on
encasing mattresses, domestic cleaning, and the use of acaricides.
The theory is that by reducing or containing the mite population,
exposure of the patient to mite allergens is also reduced, resulting in
fewer symptoms. Although these measures are simple and intuitive,
multiple factors affect mite prevalence, and mite reduction may not
result in reduction of symptoms.3,108-110 Treatment guidelines vary
with regard to allergen avoidance, particularly in relation to
asthma.111 The ARIA guidelines conclude that there is no overall
clinical beneﬁt through avoidance measures to patients already
suffering from HDM-related perennial AR and/or AA, although the
impact of avoidance on the level of HDM exposure is uncertain.26
The GINA guidelines acknowledge that measures should be
implemented wherever possible to prevent the development of
asthma and asthma symptoms and exacerbations. However,
considering that mite allergens are environmental factors that trigger
asthma symptoms, the GINA guidelines conclude that no single
avoidance measure is likely to reduce exposure to mite allergens and
an integrated approach to avoidance cannot be widely recom-
mended.112,113 Similarly, a 2015 Cochrane review has demonstrated
a lack of clear evidence to inform clinical practice in the use of HDM
reduction or avoidance measures in the treatment of atopic eczema.
The authors recommended high-quality long-term trials of such
measures.114
A Cochrane-based review of 54 randomized controlled trials
explored the clinical impact of various allergen avoidance strategies
for patients with asthma, diagnosed as sensitized to HDM allergens
using allergen-speciﬁc IgE testing. In general, the quality of trials was
poor, and even when using strict exclusion criteria to reduce the data
sets for meta-analysis, no effect of control measures was found. The
authors criticized current guidelines, suggesting that avoidance
measures are not evidence-based and that the trials were highly
selected and frequently nonrandomized.27
Data sets for HDM avoidance are less frequent for AR than for
asthma, but a similar Cochrane review for AR identiﬁed 9 trials of
suitable quality, with numbers too small for meta-analysis.28 These
studies investigated the use of impermeable bedding covers (4 trials),
acaricides (2 trials), high-efﬁciency particulate air ﬁlters (2 trials), and
a combination of approaches (1 trial). Acaricides proved to be the
most promising intervention, with a borderline success rate, but
again, no clear clinical advantages could be conﬁrmed for any
strategy.
The potential for bias in the application of inclusion criteria for
such reviews has become a controversial topic in HDM allergy,115
and some researchers have suggested that exclusion bias in the
Cochrane reviews explains a “false-negative” ﬁnding in asthma, a
criticism particularly relevant given the borderline ﬁndings for
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methodological bias in asthma meta-analyses117 and reference bias in
HDM allergy reviews.118
Until more conclusive data are available, allergen avoidance is still
being widely used as a means to control symptoms in some
patients.115 It is likely to beneﬁt children with asthma29,119; however,
the poor quality of studies on AR means that they have failed to show
conclusive evidence of the beneﬁt of avoidance.120 Also, adherence to
avoidance strategies by patients has not always been perfect, with a
probable impact on the success of the intervention.28,121
Home-based environmental intervention has been shown to be
effective when combined with a holistic approach, including reduced
allergen exposure, avoidance of tobacco smoke, improved education,
and regular assessment.29,30 However, it is important to distinguish
between the impact of allergen avoidance in an already-sensitized
population and in one in which nonsensitized individuals are at
risk, where beneﬁts in disease prevention have been observed by
some researchers.122
To illustrate the inconsistency of results, a randomized study of
the effects of a multifaceted intervention, including HDM avoidance
during pregnancy and early life, resulted in increased risk of HDM
sensitization, but better lung function in the intervention group at
age 3 years.123 In contrast, for tertiary prevention in particular,
multifaceted avoidance strategies early in life are likely to show the
greatest effect when used to modify and potentially prevent allergic
progression.124-127 A progressive intervention would identify infants
with a genetic predisposition using familial asthma as a “genetic”
proxy, then would recommend breast-feeding, allergen avoidance
strategies, and timely use of appropriate medication to control early
symptoms.127,128 The target patient population is relevant here
because intervention in childhood is effective in reducing the risk of
poor asthma control among atopic, but not nonatopic, children.31
In general, evidence on the efﬁcacy of avoidance is poor, and
reduction in mite exposure does not necessarily reduce symptoms.
No overall clinical beneﬁt has been demonstrated from avoidance
measures to patients already suffering from HDM-related perennial
AR and/or asthma, but babies and children with a genetic predis-
position to asthma may beneﬁt from mite avoidance. Further
investigation is needed on the diversity of sources of allergen expo-
sure, the aerodynamic behavior of allergen particles, and the rela-
tionship between allergen exposure and clinical effect.129
Pharmacotherapy for HDM allergy
Treatment for AR and AA caused by HDM is guided by the
ARIA7 and GINA111 guidelines and others.12,120 Symptoms can be
effectively controlled by pharmacotherapy products, which have a
long-standing and strong evidence base for both rhinitis and asthma,
and are rightly considered the cornerstone of disease management.
First-line treatment for rhinitis is by oral or intranasal second-
generation antihistamines and nasal corticosteroids, with other
useful add-on options including oral leukotriene antagonists and
antihistamine eyedrops,7 whereas asthma treatment is a stepwise
progression through inhaled corticosteroids, long-acting b2-agonists,
leukotriene modiﬁers, theophylline, and anti-IgE.112 The evidence
base for key treatment interventions demonstrates a clear division
between the strata of diagnosis between symptom-led (rhinitis,
asthma) or phenotype/endotype-led (in this case, allergy caused by
HDM) (Table I).
Many pharmacological treatments for AR have been evaluated,
but not all current drugs have been speciﬁcally researched in cases in
which HDM allergy is the underlying cause and many patientsachieve only poor or moderate control.32 We need more evidence
relating to speciﬁc treatment of HDM-related conditions. This gap
in the evidence base is not relevant in cases in which symptoms are
well managed using conventional treatments. It may, however, be
relevant given the heterogeneity of asthma and rhinitis, and the
potential for speciﬁc subsets of patients with asthma (in this case,
HDM allergy) to respond differently to different medications.12 In
cases in which symptom control by pharmacotherapy is poor, more
complete understanding of the relationship between asthma and the
various phenotypes of allergic disease3,130 could enable a more
effective choice of pharmacotherapeutic agent.
Regardless of the treatment choice, it should take into account the
severity, frequency of (re-)occurrence, and duration of symptoms, as
well as less-than-effective control and the potential for patient
aversion to long-term pharmacotherapy.12
In summary, the symptoms of both AR and AA can be effectively
controlled by the available pharmacotherapeutic agents. However,
many have not been tested speciﬁcally in the case of HDM-related
conditions and a broader evidence base is needed.
AIT: Targeting the natural history of HDM allergy
AIT is the only current medical treatment that can modify the
natural history of respiratory allergic disease. The efﬁcacy in reducing
symptom burden and medication use has been shown for both
subcutaneous and sublingual AIT (SCIT and SLIT, respectively).
SLIT has an improved safety proﬁle, combined with the advantage
of home administration and less commitment of the patient’s time.33
Few direct head-to-head studies have explored the relative safety and
efﬁcacy of these 2 approaches, so current practice relies on indirect
comparison of outcomes. The evidence base for SLIT contains more
placebo-controlled, dose-dependent, large-number trials.9 Following
calls for more robust AIT studies, evidence is now appearing from
double-blind placebo-controlled studies on the efﬁcacy, safety, and
optimal dosing of sublingual tablets.35,36 The beneﬁts extend to
patients with mild to moderate HDM-induced AA37 and enable
reduced use of inhaled corticosteroids.37
Historic concerns over safety due to systemic reactions with SCIT
may have caused hesitation regarding its widespread use. When
considering the relevance of these cases today, there are 2 key
considerations: how the management of AIT has evolved over the
years, and the relative safety proﬁle of the allergen products used for
speciﬁc preparations.
The second consideration, allergen product safety, must take into
account class-speciﬁc and drug-speciﬁc differences. A dramatically
lower systemic reaction rate has been observed for SLIT relative to
SCIT (even in the latter, though, the percentage of systemic
reactions per injection is low; w0.2%).131 HDM-allergic patients
treated with HDM SLIT tablets for 1 year also showed no sign of
IgE neosensitization to vaccine allergens.132 After 1 year of treat-
ment, IgE and IgG4 titers speciﬁc for HDM increased by a factor of
1.5 and 4, respectively, but preexisting IgE levels to puriﬁed group 1,
2, and 10 allergens were unaffected.132 Regarding HDM allergy,
comprehensive systematic reviews suggest a reliable safety proﬁle in
SLIT.9,133 It has been suggested that future generations of AIT will
use the molecular modiﬁcation of allergen proteins (hopefully
including HDM allergen proteins) to reduce allergenicity and/or
increase immunogenicity.134
Figure 3, A and B, summarizes existing clinical efﬁcacy data from
meta-analyses of SCIT and SLIT in AR and AA. Each data set ﬁrst
considers AIT across a series of allergens and then extracts a subset of
data speciﬁc to HDM allergy.
FIGURE 3. A, A summary of efficacy data for AIT in AR.135,136 Forest plot to indicate the reported efficacy for SCIT and SLIT in AR
related to HDM and to all reported allergens. The pooled estimates are mean difference between active and placebo in total symptom
scores. B, A summary of efficacy data for AIT in AA.137,138 Forest plot to indicate the reported efficacy for SCITand SLIT in AA related to
HDM and to all reported allergens. The pooled estimates are mean difference between active and placebo in total symptom scores.
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SCIT, with a signiﬁcant advantage found in favor of AIT
(P ¼ .007), and within the HDM allergy subset, 7 studies (n ¼ 173
active/175 placebo) also showed a signiﬁcant advantage
(P ¼ .0004).135 For the use of SLIT in AR, 49 studies (n ¼ 2333
active/2256 placebo) found an advantage for AIT for all allergens
(P < .00001) and 9 studies (n ¼ 232 active/232 placebo) found an
advantage for the HDM allergy subset (P ¼ .02).136
For AA, 34 studies (n ¼ 727 active/557 placebo) reported a
signiﬁcant effect for SCIT applied to all allergens (P< .00001) and 12studies (n ¼ 247 active/161 placebo) found marginal signiﬁcance for
the HDM allergy population (P¼ .048).137 Finally, data for the use of
SLIT in AA were pooled from 9 studies (n¼ 150 active/153 placebo)
and found no signiﬁcance (P ¼ .07), and only 4 studies were available
for HDM allergy patients (n¼ 55 active/53 placebo), again ﬁnding no
signiﬁcance relative to placebo (P¼ .27).138 It should be noted that the
last study was compiled using minimal data, and it contradicts more
recent systematic reviews ﬁnding advantages for SLIT.133
Allergen-speciﬁc strategies may have a role in altering the pro-
gression of respiratory allergic disease and enabling the long-term
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 3, NUMBER 6
CALDERÓN ETAL 851prevention of asthma in children with HDM allergy.139 Meta-
analyses of SLIT in children have historically yielded mixed ﬁnd-
ings, with some systematic reviews showing contradictory results in
both AA and AR.140,141 As throughout HDM allergy investigations,
trials have been of low quality, perhaps explaining these conﬂicting
results.142 The most recent ﬁndings suggest that there is now high-
quality evidence in the pediatric population for using AIT for
medication reduction while maintaining symptom control in AA.
However, there is only low-moderate quality evidence on its impact
in AR: some trials showed improvement in nasal symptom scores
and/or medication scores, but a placebo was not always included.143
The best evidence to recommend SLIT in children with AR is low to
moderate level of evidence for the prevention of asthma develop-
ment. More large randomized trials are needed, especially with
HDM SLIT in children.143
The high clinical and methodological heterogeneity in studies
of AIT in HDM allergy creates difﬁculties in extracting
information for systematic reviews and prevents pooling for meta-
analyses.9,133,144,145 Potential diversity in products may also
confound trial ﬁndings; a greater deﬁnition of allergen extract,
quality, batch-to-batch stability, and concentration may be needed
to strengthen trial validity.9,146 These limitations partly explain the
substantial gaps in our knowledge relating to the application of AIT
for HDM allergy. For example, the only data available to ascertain
optimal dosing strategies for SLIT are insufﬁcient, compromising
future guideline development,133 although in SCIT, a maintenance
dose in the range of 5 to 20 mg of major inhaled allergens has been
shown to be effective.11 A review of the 9 studies published in 2013
and 2014 on the use of SCIT and SLIT in the treatment of both AR
and AA36 conﬁrmed their safety and efﬁcacy and concluded that
optimal clinically effective doses will be established for SLIT tablets
under development in large, randomized, placebo-controlled trials
for treatment of HDM allergy. Even so, this review criticized the
dosing guidance offered for effective SLIT liquid because it was not
directly usable by physicians.36
One clear potential advantage of AIT is its ability to maintain
efﬁcacy beyond treatment discontinuation, and so another area for
exploration is the duration of treatment needed to induce a lasting
effect. A study of patients with respiratory allergy who were mon-
osensitized to mites and treated with SLIT or drug therapy for 3, 4,
or 5 years followed their clinical condition for 15 years, ﬁnding that
4 years was the optimal duration.147
Polysensitization is more prevalent in patients with moderate to
severe respiratory allergies in the United States, where multiallergen
treatment is predominant, and Europe, where single-allergen treat-
ment targeting the predominant allergen is preferred.24 Large-scale,
double-blind, placebo-controlled trials of grass pollen sublingual
tablets have shown that polysensitized patients gained as much
improvement as monosensitized patients.24 However, data relating
to HDM are less robust, although conﬁrming that the symptoms of
HDM-sensitized patients improved with HDM SLIT regardless of
whether they were monosensitized to HDM or polysensitized to
other additional unrelated allergens.148,149 Several authors have
pointed out that additional research is needed on simultaneous
therapy with more than 2 allergens to determine whether single-
allergen and multiallergen immunotherapy elicit distinct responses
in monosensitized and polysensitized patients, and have called for
more robust data to validate the use of multiallergen immunotherapy
in polysensitized patients in practice.24,150
Although SCIT and SLIT have both been shown to be effective
in reducing symptoms of HDM-induced AR and AA, and inreducing use of pharmacotherapy, many studies are limited by their
high heterogeneity in design and deﬁnition of allergen extract,
quality, batch-to-batch stability, and concentration. Recent double-
blind placebo-controlled studies on SLIT tablets have shown beneﬁts
for patients with AR and/or mild to moderate HDM-induced AA.
Future research should also include the elucidation of disease-
modifying factors that confound or support AIT, the recom-
mended time for therapy initiation, and the subsets of HDM allergy
patients most responsive to AIT. Unlike much of the existing
literature, future trials should use standardized outcome measures,
deﬁnitions, and parameters.CONCLUSIONS
HDM allergy plays a critical role in AR and AA, but delays on
the part of patients in seeking treatment and on the part of
physicians in achieving accurate diagnosis, coupled with lack of
access to specialist allergy diagnosis, contribute to reduced
treatment effectiveness.
Despite the range of effective pharmaceutical products available
to treat respiratory allergic disease, intermittent self-medication or
poor patient adherence to prescribed treatment may result in poor
control of symptoms, and the beneﬁts end when treatment stops.
Although strong evidence supports pharmacological treatment of
rhinitis and asthma in general, direct evidence of pharmacological
impact on HDM allergyerelated conditions is heterogeneous and
weaker. The option of AIT is not widespread, possibly underused
in clinical practice, and dependent on speciﬁc identiﬁcation of
HDM allergy. Allergen avoidance, like AIT, depends on identi-
fying HDM as the cause of the immune response.
Accurate diagnosis—not only of the species of dust mite but
preferably the allergen group—is one of the major limiting
factors in the provision of adequate treatment for HDM-related
respiratory disease. In addition to the clinical problems
mentioned, the diagnostic techniques of SPT and speciﬁc IgE
testing can be hampered by cross-reactivity and made more
complicated by polysensitization. The increasing use of CRD has
strong potential to complement these 2 standard techniques and
the use of recombinant allergens can compensate for the
variability of natural allergen extracts. Together these techniques
can identify the individual molecules to which a patient is
sensitized and can distinguish between true polysensitization and
cross-reactivity. CRD can also be used to monitor the course of
AIT and to assess compliance. However, the techniques may be
available only to those individuals whose condition is particularly
complex and who are lucky enough to be in specialist care.
Although avoidance of HDM is widely recommended as a
strategy, evidence for its efﬁcacy is variable and the ARIA and
GINA guidelines conclude that no single avoidance measure is
likely to reduce exposure to mite allergens, and even an inte-
grated approach to avoidance cannot be widely recommended.
Again, poor patient compliance can limit the effectiveness of
avoidance tactics, and measuring compliance in a domestic
setting over a long period of time is extremely challenging.
Avoidance studies suffer from heterogeneity in clinical trial
design, end point deﬁnition, and validated outcomes. The
strongest evidence suggests that the main beneﬁt of avoidance
may be in the case of targeted multiple avoidance measures to
avoid the development of asthma in atopic children.
Well-designed meta-analyses indicate that SCIT and SLIT are
both effective in reducing symptoms of HDM-induced AR and
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the course of disease, and its beneﬁts last after treatment ends.
Recent randomized, double-blind, placebo-controlled trials are
contributing robust evidence on the safety and efﬁcacy of sub-
lingual tablets. Future trials should address historic shortcomings
in design to provide an improved evidence base that can enable
reﬁnement of the guidelines to offer more complete guidance on
allergen-speciﬁc strategies.
We believe that this review has identiﬁed a need for deeper
knowledge among physicians on the extent and impact of HDM
allergy in respiratory disease, as well as for further development
and standardization of access to molecular allergy diagnosis.
Furthermore, the development of robust better-designed clinical
trials to explore the utility of allergy-speciﬁc approaches, and
uptake of resulting data into guidance for physicians on more
effective diagnosis and therapy of HDM respiratory allergy in
practice, is critical.
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